Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Study of Regorafenib and Nivolumab Plus Chemotherapy in Patients With Unresectable Advanced/Recurrent Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma
Conditions
Interventions
Regorafenib
Nivolumab
+2 more
Locations
1
Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Start Date
June 6, 2022
Primary Completion Date
April 14, 2024
Completion Date
August 25, 2025
Last Updated
April 9, 2026
NCT06340711
NCT05969860
NCT05745857
NCT04895709
NCT04704661
NCT06901531
Lead Sponsor
National Cancer Center Hospital East
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions